-
Published 6/3/2026
Soto Albrecht YE, Morrow RM, Kenney D, Olali AZ, Wacquiez A, Chehadeh N, Cen Z, Haltom JA, Chen I, Ranshing SS, Widjaja GA, Angelin A, Tintos-Hernandez JA, Xie W, Potluri P, Lott MT, Zhang S, Saeed M, Murdock DG, Weiss SR, Douam F, Wallace DC. Mitochondrial OXPHOS restricts SARS-CoV-2 replication. Sci Adv. 2026 Jun 05; 12(23):eadz3081. PMID: 42234733.
-
Published 4/28/2026
Shastry A, Hiller BE, Sanders NL, Tseng AE, Kothari J, O'connell AK, Gertje HP, Ha CT, Murzin E, Traber KE, Lederer JA, Jones MR, Douam F, Beach TG, Remick DG, Crossland NA, Monti S, Campbell JD, Mizgerd JP. Sub-phenotypes of pneumonia defined by pulmonary histopathological features. Am J Respir Crit Care Med. 2026 Apr 28. PMID: 42089675.
-
Published 4/14/2026
Streicher F, Kenney D, Caval V, Chazal M, Aicher S-M, Gracias S, Adams S, Matsuo M, Roesch F, Douam F, Jouvenet N. Type I and III interferon responses restrict infection by tick-borne orthoflaviviruses through IFI6. J Virol. 2026 May 19; 100(5):e0076025. PMID: 41979927.
-
Published 1/5/2026
Subramaniam S, Napoleon MA, Lotfollahzadeh S, Kamal MH, Kurniawan H, Francis C, Elsadawi M, Wu Wong DJ, Kenney D, Douam F, Bosmann M, Whelan SA, Cabral H, Burks EJ, Zhao G, Kolachalama VB, Ravid K, Chitalia VC. Tryptophan metabolism reprogramming potentially contributes to the prothrombotic milieu in mice and humans with SARS-CoV-2. Blood Vessel Thromb Hemost. 2026 Feb; 3(1):100128. PMID: 41743170.
-
Published 9/29/2025
Unali G, Douam F. Orthoflavivirus Vaccine Platforms: Current Strategies and Challenges. Vaccines (Basel). 2025 Sep 29; 13(10). PMID: 41150403.